Loading
A phase 2 trial of Dexamethasone, Vincristine, Rituximab, Clofarabine, Cyclophosphamide, Etoposide, Aldesleukin, Asparaginase, Methotrexate, Mercaptopurine, Cytarabine, Mitoxantrone, Teniposide and Vinblastine in Acute lymphoblastic leukaemia, run by St. Jude Children's Research Hospital, completed.
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma is a phase 2 interventional study registered as NCT01700946 by St. Jude Children's Research Hospital, with 80 participants recorded, started 2013-04-15 and reaching its primary completion in 2021-07-24. Interventions recorded: dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone, allogeneic hematopoietic stem cell transplantation, CliniMACS. Conditions recorded: Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma.
Linked to the drug Teniposide because the registry names it among its interventions and Acute lymphoblastic leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
80 enrolled.
95% CI 66.6 to 99.2; Figures from the ClinicalTrials.gov results section (first posted 2022-09-28), not from a publication · 95% CI 33.0 to 73.2 · 95% CI 55.95 to 83.85
Source95% CI 56.8 to 94.3; Figures from the ClinicalTrials.gov results section (first posted 2022-09-28), not from a publication · 95% CI 33.2 to 73.4 · 95% CI 51.04 to 79.9
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| 3-year Overall Survival Rate of Patients With Relapsed ALLprimary | STANDARD RISK | 18 | 94.4% | - | - | link |
| HIGH RISK | 24 | 55.5% | ||||
| All Patients Enrolled on the Study | 42 | 72.63% | ||||
| 3-year Event-free Survival Rates in Patients With Relapsed ALLprimary | STANDARD RISK | 18 | 83.3% | - | - | link |
| HIGH RISK | 24 | 55.7% | ||||
| All Patients Enrolled on the Study | 42 | 67.83% |
Shares Clofarabine, Mercaptopurine, Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase), Cytarabine and the tag pipeline.
Shares Mercaptopurine, Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase), Cytarabine, Methotrexate and the tag pipeline.
Shares Mercaptopurine, Cytarabine, Methotrexate, Dexamethasone and the tag pipeline.
Shares Mitoxantrone, Cytarabine, Dexamethasone, Vincristine and the tag pipeline.
Shares Mercaptopurine, Cytarabine, Methotrexate, Dexamethasone and the tag pipeline.
Shares Cytarabine, Methotrexate, Vincristine, Etoposide and the tag pipeline.
Shares Cytarabine, Methotrexate, Dexamethasone, Vincristine and the tag pipeline.
Shares Mitoxantrone, Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase), Cytarabine, Methotrexate and the tag pipeline.